Assessment of the topoisomerase I gene copy number as a predictive biomarker of objective response to irinotecan in metastatic colorectal cancer

Scandinavian Journal of Gastroenterology

Volumn 49, Issue 1, 2014, Pages 84-91

  Nygård, Sune Boris ^a   Christensen, Ib Jarle ^b   Nielsen, Signe Lykke ^a   Nielsen, Hans Jorgen ^a,c   Brünner, Nils ^a   Spindler, Karen Lise Garm ^d,e  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

^d LILLEBAELT HOSPITAL   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Biomarker; Colorectal cancer; DNA topoisomerase I; Irinotecan

Indexed keywords

BEVACIZUMAB; DNA TOPOISOMERASE; FLUOROPYRAMIDINE; FLUOROURACIL DERIVATIVE; IRINOTECAN; OXALIPLATIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CENTROMERE; CHROMOSOME 20; CONTROLLED STUDY; DIPLOIDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FLUORESCENCE MICROSCOPE; GENE DOSAGE; HUMAN; HUMAN TISSUE; IMMUNOLOGY TEST KIT; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MIDDLE AGED; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PATIENT HISTORY OF CHEMOTHERAPY; PATIENT HISTORY OF RADIOTHERAPY; PRACTICE GUIDELINE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DNA TOPOISOMERASES, TYPE I; FEMALE; GENE DOSAGE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84890945493     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2013.856464     Document Type: Article

References (35)

1. Engholm G, Ferlay J, Christensen N, et al. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 5.3 (April 2013). Association of the Nordic Cancer Registries. Danish Cancer Society. http: // ancr.nu.
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer 2013;49: 1374-403
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127: 2893-917
4. Mitry E, Rollot F, Jooste V, Guiu B, Lepage C, Ghiringhelli F, et al. Improvement in survival of metastatic colorectal cancer: Are the benefits of clinical trials reproduced in population-based studies? Eur J Cancer 2013;49: 2919-25
5. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J CliNoncol 2004; 22: 229-37
6. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J CliNoncol 2005;23: 4866-75
7. NCCN Guidelines Version 3.2013 Colon Cancer: National Comprehensive Cancer Network. http: //nccn.org/professionals/ physician-gls/f-guidelines.asp
8. NCCN Guidelines Version 4.2013 Rectal Cancer: National Comprehensive Cancer Network. http: //nccn.org/professionals/ physician-gls/f-guidelines.asp
9. Jensen NF, Smith DH, Nygard SB, Romer MU, Nielsen KV, Brunner N. Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer. Scand J Gastroenterol 2012;47: 340-55
10. Pommier Y. DNA topoisomerase I inhibitors: Chemistry, biology, and interfacial inhibition. Chem Rev 2009;109: 2894-902
11. Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 2010;17: 421-33
12. McLeod HL, Keith WN. Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity. Br J Cancer 1996;74: 508-12
13. Romer MU, Jensen NF, Nielsen SL, Muller S, Nielsen KV, Nielsen HJ, et al. TOP1 gene copy numbers in colorectal cancer samples and cell lines and their association to in vitro drug sensitivity. Scand J Gastroenterol 2012;47: 68-79
14. Eng WK, McCabe FL, Tan KB, Mattern MR, Hofmann GA, Woessner RD, et al. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol 1990;38: 471-80
15. Jansen WJ, Zwart B, Hulscher ST, Giaccone G, Pinedo HM, Boven E. CPT-11 in human colon-cancer cell lines and xenografts: Characterization of cellular sensitivity determinants. Int J Cancer 1997;70: 335-40
16. Bandyopadhyay K, Gjerset RA. Protein kinase CK2 is a central regulator of topoisomerase I hyperphosphorylation and camptothecin sensitivity in cancer cell lines. Biochemistry 2011;50: 704-14
17. Horisberger K, Erben P, Muessle B, Woernle C, Stroebel P, Kaehler G, et al. Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer. Anticancer Drugs 2009;20: 519-24
18. Kostopoulos I, Karavasilis V, Karina M, Bobos M, Xiros N, Pentheroudakis G, et al. Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy. BMC Cancer 2009;9: 339
19. Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: Results from the UK MRC FOCUS trial. J CliNoncol 2008;26: 2690-8
20. Paradiso A, Xu J, Mangia A, Chiriatti A, Simone G, Zito A, et al. Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients. Int J Cancer 2004;111: 252-8
21. Vallbohmer D, Iqbal S, Yang DY, Rhodes KE, Zhang W, Gordon M, et al. Molecular determinants of irinotecan efficacy. Int J Cancer 2006;119: 2435-42
22. Romer MU, Nygard SB, Christensen IJ, Nielsen SL, Nielsen KV, Muller S, et al. Topoisomerase 1(TOP1) gene copy number in stage III colorectal cancer patients and its relation to prognosis. Mol Oncol 2012;7: 101-11
23. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45: 228-47
24. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): Explanation and elaboration. BMC Med 2012; 10: 51
25. De Angelis PM, Clausen OP, Schjolberg A, Stokke T. Chromosomal gains and losses in primary colorectal carcinomas detected by CGH and their associations with tumour DNA ploidy, genotypes and phenotypes. Br J Cancer 1999;80: 526-35
26. De Angelis PM, Stokke T, Beigi M, Mjaland O, Clausen OP. Prognostic significance of recurrent chromosomal aberrations detected by comparative genomic hybridization in sporadic colorectal cancer. Int J Colorectal Dis 2001;16: 38-45
27. Korn WM, Yasutake T, Kuo WL, Warren RS, Collins C, Tomita M, et al. Chromosome arm 20q gains and other genomic alterations in colorectal cancer metastatic to liver, as analyzed by comparative genomic hybridization and fluorescence in situ hybridization. Genes Chromosomes Cancer 1999;25: 82-90
28. Carvalho B, Postma C, Mongera S, Hopmans E, Diskin S, van de Wiel MA, et al. Multiple putative oncogenes at the chromosome 20q amplicon contribute to colorectal adenoma to carcinoma progression. Gut 2009;58: 79-89
29. Smith DH, Christensen IJ, Jensen NF, Markussen B, Romer MU, Nygard SB, et al. Mechanisms of topoisomerase I (TOP1) gene copy number increase in a stage III colorectal cancer patient cohort. PLoS ONE 2013;8: E60613
30. Varella-Garcia M, Diebold J, Eberhard DA, Geenen K, Hirschmann A, Kockx M, et al. EGFR fluorescence in situ hybridisation assay: Guidelines for application to non-small-cell lung cancer. J Clin Pathol 2009;62: 970-7
31. Dahabreh IJ, Linardou H, Kosmidis P, Bafaloukos D, Murray S. EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: A systematic review and meta-analysis in non-small-cell lung cancer. AnNoncol 2011;22: 545-52
32. Nielsen KV, Brunner N. Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 2011;103: 352-3
33. Aust DE, Muders M, Kohler A, Schmidt M, Diebold J, Muller C, et al. Prognostic relevance of 20q13 gains in sporadic colorectal cancers: A FISH analysis. Scand J Gastroenterol 2004;39: 766-72
34. Xie T, D' Ario G, Lamb JR, Martin E, Wang K, Tejpar S, et al. A comprehensive characterization of genome-wide copy number aberrations in colorectal cancer reveals novel oncogenes and patterns of alterations. PLoS ONE 2012;7: E42001
35. Van Cutsem E, Labianca R, Bodoky G, Barone C, Aranda E, Nordlinger B, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J CliNoncol 2009; 27: 3117-25